Previous 10 | Next 10 |
BEDMINSTER, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audi...
BEDMINSTER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Group Infe...
Matinas BioPharma Slumps After Amarin Case Verdict Matinas BioPharma ( MTNB ) stock slumped after a US District Court decided to invalidate Amarin Corporation's (AMRN) Vascepa. While the verdict is ostensibly in favor of generic drugs, Matinas stock reacted negatively to the news. Howeve...
Matinas BioPharma ( MTNB -21.4% ) on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa, says The Nevada District Court’s ruling on the Vascepa patents has no impact on the validity of the issued or pending patents c...
BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa a...
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2019 Results Earnings Conference Call March 09, 2020, 08:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terry Matkovits - Chief Development ...
Matinas Biopharma (NYSEMKT: MTNB ): Q4 GAAP EPS of -$0.04 misses by $0.01 . More news on: Matinas BioPharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated ENHANCE-IT study of MAT9001 against Vascepa ® . Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis Q1 2020 Management to host conference call today, Monday, March 9 th, at 8:00 a.m. ET BEDMINS...
BEDMINSTER, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live aud...
– Part 2 efficacy portion of EnACT expected to commence Q1 2020 – BEDMINSTER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has c...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...